切换至 "中华医学电子期刊资源库"
高级检索
中华临床医师杂志(电子版)

中华临床医师杂志(电子版) ›› 2024, Vol. 18 ›› Issue (02) : 178 -182. doi: 10.3877/cma.j.issn.1674-0785.2024.02.011

临床研究

血清WISP1水平与2型糖尿病患者血尿酸升高的相关性
孙琳1, 韩萍萍2, 张碧琳2, 张军霞1,†()   
  1. 1. 510515　广州，南方医科大学第一临床医学院;430070　武汉，解放军中部战区总医院内分泌科
    2. 430070　武汉，解放军中部战区总医院内分泌科
  • 收稿日期:2023-12-12 出版日期:2024-02-15
  • 通信作者: 张军霞
  • 基金资助:
    湖北省卫生健康科研基金重点支撑项目(WJ2021Z010)

Serum levels of WISP1correlate with elevated serum uric acid in type 2 diabetic patients

Lin Sun1, Pingping Han2, Bilin Zhang2, Junxia Zhang1,†()   

  1. 1. The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China;Department of Endocrinology, Central Theater Command General Hospital of the Chinese PLA, Wuhan 430070, China
    2. Department of Endocrinology, Central Theater Command General Hospital of the Chinese PLA, Wuhan 430070, China
  • Received:2023-12-12 Published:2024-02-15
  • Corresponding author: Junxia Zhang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

孙琳, 韩萍萍, 张碧琳, 张军霞. 血清WISP1水平与2型糖尿病患者血尿酸升高的相关性[J]. 中华临床医师杂志(电子版), 2024, 18(02): 178-182.

Lin Sun, Pingping Han, Bilin Zhang, Junxia Zhang. Serum levels of WISP1correlate with elevated serum uric acid in type 2 diabetic patients[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 178-182.

目的

探讨2型糖尿病（T2DM）患者中血清Wnt1诱导信号通路蛋白-1（WISP1）水平与血尿酸浓度的相关性。

方法

随机招募作者医院内分泌科T2DM患者146例，根据血尿酸的中位数分为高尿酸组和低尿酸组。测量2组身高、体重、腰围、臀围、内脏脂肪面积等一般人体学指标。检测血尿酸（SUA）、肝肾功能、血糖、血脂、C反应蛋白（CRP）、糖化血红蛋白A1c（HbA1c）、空腹C肽等指标。ELISA法测定血清WISP1含量。

结果

与低尿酸组比较，高尿酸组的血清WISP1水平更高（P=0.004）。Spearman相关分析显示，血清WISP1水平与SUA（r=0.139，P=0.040）、CRP（r=0.203，P=0.004）、HbA1c（r=0.185，P=0.006）呈正相关。多元逐步回归分析显示，WISP1水平独立影响血尿酸水平（β=0.220，P<0.001)。

结论

血清WISP1与T2DM患者血尿酸升高独立正相关。

关键词: Wnt1诱导信号通路蛋白-1, 2型糖尿病, 血尿酸, 胰岛素抵抗
Objective

To investigate the correlation between serum Wnt1 induced signaling pathway protein 1 (WISP1) levels and serum uric acid (SUA) in patients with type 2 diabetes mellitus (T2DM).

Methods

A total of 146 T2DM patients were randomly recruited from the department of endocrinology of the authors' hospital. According to the median level of SUA, the patients were divided into either a high uric acid group or a low uric acid group. Height, weight, waist circumference, hip circumference, and visceral fat area were measured. The levels of SUA, hepatorenal function parameters, blood glucose, blood lipid, C-reactive protein (CRP), glycosylated hemoglobin A1c (HbA1c), and fasting C-peptide were detected. ELISA was used to measure the serum levels of WISP1.

Results

The patients in the high uric acid group had higher serum WISP1 levels than those in the low uric acid group (P=0.004). Spearman correlation analysis showed that WISP1 was positively correlated with SUA (r=0.139, P=0.040), CRP (r=0.203, P=0.004), and HbA1c (r=0.185, P=0.006). Multiple stepwise regression analysis demonstrated that WISP1 independently contributed to elevated serum uric acid levels (β=0.220, P<0.001).

Conclusion

Serum WISP1 independently and positively correlates with elevated SUA in type 2 diabetic patients.

Key words: Wnt1 induced signaling pathway protein-1 (WISP1), Type 2 diabetes mellitus, Blood uric acid, Insulin resistance
表1 2组临床资料及血指标的比较
项目 高尿酸组（n=73） 低尿酸组（n=73） t/χ2值 P值
男性/女性 59/14 39/34 12.415a 0.001
年龄（岁，） 46.82±12.74 51.81±10.87 -3.018 0.003
病程[月，M（P25，P75）] 5（1，12） 6（1，36） -2.903 0.004
吸烟[例（%）] 27（36.99） 21（28.77） 1.119a 0.189
饮酒[例（%）] 10（13.69） 12（16.44） 0.214a 0.818
高血压[例（%）] 23（31.51） 24（32.88） 0.031a 1.000
高脂血症[例（%）] 19（26.03） 17（23.29） 0.147a 0.848
BMI（kg/m2，） 26.06±3.19 24.80±3.59 2.539 0.012
WC（cm，） 91.17±10.31 85.47±10.09 3.913 <0.001
WHR（） 0.92±0.06 0.89±0.07 2.602 0.01
VFA（cm2，） 112.48±38.13 100.62±40.19 2.094 0.037
SBP（mmHg，） 125.81±14.74 120.60±16.47 2.281 0.024
DBP（mmHg，） 79.93±10.21 77.60±9.76 1.639 0.103
SCr（μmol/L，） 62.93±17.13 55.23±13.76 3.590 <0.001
SUA[μmol/L，M（P25，P75）] 368.00（333.00，434.00） 249.00（202.75，273.00） 13.345 <0.001
CRP[mg/L，M（P25，P75）] 1.75（1.02，3.89） 1.21（0.68，2.75） 1.361 0.178
TG[mmol/L，M（P25，P75）] 2.20（1.45，3.82） 1.50（1.05，2.43） 3.356 0.001
TC（mmol/L，） 5.05±1.19 4.89±1.24 0.888 0.375
LDL-C（mmol/L，） 2.75±0.76 2.80±0.84 -0.141 0.888
HDL-C（mmol/L，） 1.26±0.53 1.22±0.26 0.698 0.486
FBG（mmol/L，） 9.33±3.39 9.06±4.05 0.487 0.627
HbA1c（%，） 13.51±5.75 13.81±6.98 -0.319 0.750
FCP[nmol/L，M（P25，P75）] 0.72（0.52，0.91） 0.65（0.35，0.87） 1.765 0.080
HOMA2-IR[M（P25，P75）] 1.92（1.46，2.39） 1.75（1.36，2.43） 1.164 0.247
WISP1[pg/ml，M（P25，P75）] 52.49（38.25，76.57） 49.89（37.44，67.11） 2.939 0.004
表2 2型糖尿病患者血尿酸的独立影响因素分析
独立变量 偏回归系数 标准误 标准化偏回归系数 t值 P值
常数项 316.947 23.399 - 13.545 <0.001
性别（男/女） -54.103 13.192 -0.259 -4.101 <0.001
WISP1（pg/ml） 0.395 0.111 0.220 3.561 <0.001
TG（mmol/L） 9.896 3.252 0.192 3.043 0.003
1
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications[J]. Nat Rev Endocrinol, 2018,14(2): 88-98.
2
Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia[J]. Curr Opin Rheumatol, 2013, 25(2): 210-216.
3
Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes[J]. Diabetes Care, 2009, 32(9): 1737-1742.
4
Chang CC, Wu CH, Liu LK, et al. Association between serum uric acid and cardiovascular risk in nonhypertensive and nondiabetic individuals: The Taiwan I-Lan longitudinal aging study[J]. Sci Rep, 2018, 8(1): 5234.
5
Cicero AFG, Fogacci F, Giovannini M, et al. Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study[J]. Sci Rep, 2018, 8(1): 11529.
6
Murahovschi V, Pivovarova O, Ilkavets I, et al. WISP1 is a novel adipokine linked to inflammation in obesity[J]. Diabetes, 2015, 64(3): 856-866.
7
Sahin Ersoy G, Altun Ensari T, Subas S, et al. WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus[J]. J Matern Fetal Neonatal Med, 2017, 30(8): 942-946.
8
Klimontov V, Bulumbaeva D, Fazullina O, et al. Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes[J]. Journal of cell communication and signaling, 2020, 14(1): 101-109.
9
Yaribeygi H, Atkin S, Sahebkar A. Wingless-type inducible signaling pathway protein-1 (WISP1) adipokine and glucose homeostasis[J]. J Cell Physiol, 2019, 234(10): 16966-16970.
10
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志,2021, 13(4): 315-409.
11
Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program[J]. Diabetes Care, 1998, 21(12): 2191-2192.
12
Su SY, Lin TH, Liu YH, et al. Sex difference in the associations among obesity-related indices with hyperuricemia in a large Taiwanese population study[J]. Nutrients, 2023, 15(15):3419.
13
Zhang J, Zhang Y, Deng W, et al. Elevated serum uric acid is associated with angiotensinogen in obese patients with untreated hypertension[J]. J Clin Hypertens (Greenwich), 2014, 16(8): 569-574.
14
Zhang JX, Lin X, Xu J, et al. Hyperuricemia inhibition protects SD rats against fructose-induced obesity hypertension via modulation of inflammation and renin-angiotensin system in adipose tissue[J]. Exp Clin Endocrinol Diabetes, 2021, 129(4): 314-321.
15
Ding C, Du F, Li L, et al. Synergistic effect of blood lipids and uric acid on periodontitis in patients with type 2 diabetes[J]. Am J Transl Res, 2023, 15(2): 1430-1437.
16
Zhou Q, Ke S, Yan Y, et al. Serum uric acid is associated with chronic kidney disease in elderly Chinese patients with diabetes[J]. Ren Fail, 2023, 45(1): 2238825.
17
孙茹蓉, 徐婷, 谢雯, 等. 高尿酸血症危险因素的数据挖掘及关联规则研究[J/OL]. 中华临床医师杂志(电子版), 2020, 14(10): 835-839.
18
Jung TW, Kang C, Goh J, et al. WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling[J]. J Cell Physiol, 2018, 233(8): 6077-6087.
19
Barchetta I, Cimini FA, Capoccia D, et al. WISP1 is a marker of systemic and adipose Tissue inflammation in dysmetabolic subjects with or without type 2 diabetes[J]. J Endocr Soc, 2017, 1(6): 660-670.
20
Cheng Y, Du X, Zhang B, et al. Increased serum WISP1 levels are associated with lower extremity atherosclerotic disease in patients with type 2 diabetes mellitus[J]. Exp Clin Endocrinol Diabetes, 2022, 130(4): 248-253.
21
Hörbelt T, Tacke C, Markova M, et al. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes[J]. Diabetologia, 2018, 61(9): 2054-2065.
22
Toyoki D, Shibata S, Kuribayashi-Okuma E, et al. Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2[J]. Am J Physiol Renal Physiol, 2017, 313(3): F826-F834.
23
aldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome[J]. Diabetes, 2011, 60(4): 1258-1269.
[1] 何金梅, 尹立雪, 谭静, 张文军, 王锐, 任梅, 廖明娇. 超声心肌做功技术对2型糖尿病患者潜在左心室心肌收缩功能损伤的评价[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1029-1035.
[2] 赵帅, 王伟, 李瑞奇, 周家杰, 王道荣. 3D腹腔镜下袖状胃切除术治疗肥胖合并2型糖尿病的临床疗效及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 146-149.
[3] 刘盾, 潘晟. 不同入路腹腔镜袖状胃切除术用于肥胖症合并2型糖尿病的效果[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 150-154.
[4] 谷先勇, 徐娟. 特发性肺纤维化合并T2DM炎症水平与预后相关性分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(05): 721-723.
[5] 王欢, 张英慧, 张德伟, 金艳华, 辛雨, 谌卫, 郭志勇, 张艳宁, 关欣. 泌尿系结石相关梗阻性肾病及碎石术后急性肾损伤发生的危险因素分析[J]. 中华肾病研究电子杂志, 2023, 12(06): 323-328.
[6] 程莉, 章晓良. 血尿酸和胱抑素C与糖尿病视网膜病变患者合并糖尿病肾病的关系及影响因素[J]. 中华肾病研究电子杂志, 2023, 12(04): 194-199.
[7] 薛念余, 张盛敏, 吴凌恒, 沙蕾, 童揽月, 沈崔琴, 李朝军, 杜联芳. 研究血清胆红素对2型糖尿病患者心脏结构发生改变前心肌功能的影响[J]. 中华临床医师杂志(电子版), 2023, 17(09): 1004-1009.
[8] 韩家超, 王飞飞, 柳子宁, 胡冀陶, 孟泽松, 雒月云, 王贵英. 二甲双胍的作用机制研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(03): 349-355.
[9] 陶璐, 初楠, 韩洁, 白春英, 逄雯丽, 余海源. 血清PECAM-1、Sirt1水平与2型糖尿病患者颈动脉粥样硬化的关系[J]. 中华临床医师杂志(电子版), 2023, 17(03): 291-296.
[10] 王嘉琳, 宋青. 妊娠合并胰岛素抵抗诊治的研究进展[J]. 中华产科急救电子杂志, 2024, 13(01): 29-32.
[11] 陈晓佩, 余丹, 潘君, 孔佳超, 李欢, 吴天凤. SGLT2抑制剂对中老年糖尿病患者血清FGF21水平的影响[J]. 中华老年病研究电子杂志, 2023, 10(03): 35-38.
[12] 李翔, 刘堂盛. 奥硝唑联合牙周基础治疗老年2型糖尿病患者慢性牙周炎疗效分析[J]. 中华老年病研究电子杂志, 2023, 10(03): 39-42.
[13] 钱昊, 李振振. 代谢综合征与动脉粥样硬化性疾病相关性研究现状与进展[J]. 中华肥胖与代谢病电子杂志, 2023, 09(04): 267-273.
[14] 汪赓, 夏泽锋, 陶凯雄. 代谢手术在非肥胖型2型糖尿病中的治疗效果及研究进展[J]. 中华肥胖与代谢病电子杂志, 2023, 09(03): 155-160.
[15] 李锦亮, 曾茂娟, 钟金宝, 何伟强, 林文新. 司美格鲁肽对肥胖2型糖尿病患者皮肤微循环功能的影响[J]. 中华肥胖与代谢病电子杂志, 2023, 09(03): 192-196.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号